\documentclass[11pt]{article} \usepackage[margin=1in]{geometry} \usepackage{amsmath} \usepackage{amssymb} \usepackage{booktabs} \usepackage[colorlinks=true, linkcolor=black, citecolor=black, urlcolor=blue]{hyperref} % --- skin palette: rust (the evidence), ochre (the marketing myth) --------- \definecolor{stepsreal}{HTML}{7C3A1C} \definecolor{stepsmyth}{HTML}{6B530C} \definecolor{stepsslate}{HTML}{3F4D57} \title{Ten Thousand Steps Was Never a Real Number} \author{The Science Journaling Club} \date{Field Notes --- Paper Analysis --- Public Health} \begin{document} \maketitle \begin{abstract} In 1965 a Japanese clock company named a pedometer \textit{manpo-kei} --- ``10,000-step meter'' --- and sold it into the fitness wave building around that year's Tokyo Olympics. No trial produced that number; no physiologist chose it. It was a product name, and it outlived the product by sixty years, ending up as the default daily step goal on phones and fitness trackers belonging to people who have never heard of the company that invented it. In August 2025, a team led by Melody Ding pooled 57 device-measured step-count studies --- the broadest review of its kind to date, spanning mortality, cardiovascular disease, cancer, dementia, depression, diabetes, and falls in a single analysis --- and found something more interesting than ``the number is wrong.'' Compared with 2{,}000 steps a day, walking 7{,}000 cuts all-cause mortality risk by 47\%, dementia risk by 38\%, and fall risk by 28\% \cite{ding2025}. But the curves do not all behave the same way. Some bend hard around 5{,}000--7{,}000 steps and barely improve after that point. Others --- cardiovascular mortality and cancer mortality among them --- keep falling in something close to a straight line, with no plateau in the data at all. Seven thousand is not a magic number either. It is just the most honest one anyone has offered so far. \end{abstract} %============================================================================ \section{A Number With a Birthday} Pull out a phone. Somewhere in its health app, almost certainly, sits a daily step goal, and almost certainly that goal is 10{,}000. Nobody set it for you personally, and nobody asked your age, your resting heart rate, or whether you have knees left to spare. The number simply arrived, pre-loaded, treated by software and by most people using it as though it carried the same clinical standing as a vaccine schedule or a cholesterol target. It does not. We went looking for the trial that established 10{,}000 steps a day as a health threshold, the way one can go looking for the trials behind ``150 minutes of moderate activity a week.'' There is not one. The paper that sent us down this path says so directly: a 2019 cohort study of older women, published in \textit{JAMA Internal Medicine}, states plainly that ``the origin of the goal of 10{,}000 steps per day is unclear'' and that it ``likely derives from the trade name of a pedometer sold in 1965'' \cite{lee2019}. That is not a claim repeated by wellness bloggers. It is a peer-reviewed epidemiology paper telling its own readers, in its introduction, that the number it is about to test has no such pedigree. We did not take that sentence on faith. We traced the citation trail it points to, confirmed the company and the year independently, and then went to find out what a large, current, multi-outcome meta-analysis says the number should actually be. That paper, \cite{ding2025}, is the real subject of this field note; the marketing history is the hook, and the dose-response curve is the substance. %============================================================================ \section{Manpo-Kei: What the Watch Company Actually Sold} The product was called the \textit{manpo-kei}. In Japanese, \textit{man} is 10{,}000, \textit{po} is step, and \textit{kei} is meter or gauge --- a ``10{,}000-step meter,'' named for exactly what it displayed and nothing more \cite{lee2019}. It was made and sold in 1965 by Yamasa Tokei Keiki, a clock and instrument manufacturer, into a Japan that had just hosted the 1964 Tokyo Olympics and was riding a genuine boom in public enthusiasm for fitness and walking. Ten thousand is a good number for a product name: round in decimal, easy to say, easy to print on a dial, large enough to sound aspirational without sounding impossible. None of those are properties a dose-response curve is obligated to share. As far as the historical record traced by later exercise-science literature shows, nobody in 1965 ran a study comparing health outcomes across step counts and found the curve did something special at 10{,}000. The number came from a naming meeting, not a laboratory. %============================================================================ \section{The Slogan Outgrows Its Packaging} A catchy product name is not, by itself, enough to become durable global health folklore. Walking clubs organized around the round number, and each new generation of researchers picked it up as a convenient, pre-existing benchmark rather than a figure they were newly proposing from evidence. By 2004, when Catrine Tudor-Locke and David Bassett published the paper that gave the field its standard step-count categories --- sedentary, low active, somewhat active, active, highly active --- 10{,}000 steps a day was already so entrenched as the public benchmark for ``active'' that the category system was built to accommodate it, explicitly as a widely recognized target rather than as a figure their own data had newly derived \cite{tudorlocke2004}. A follow-up paper four years later, co-authored with the Japanese physical-activity researcher Yoshiro Hatano, reached a similar diagnosis: a good round number, adopted worldwide, resting on much thinner evidence than its ubiquity implied \cite{tudorlocke2008}. By 2023, physical-activity researchers writing in the \textit{British Journal of Sports Medicine} gave the whole history a title --- ``Journey of a Thousand Miles: From Manpo-Kei to the First Steps-Based Physical Activity Recommendations'' --- treating the pedometer's marketing copy as the acknowledged starting point of a literature that only later caught up to it \cite{stamatakis2023}. \begin{center} \small \begin{tabular}{rl} \toprule \textbf{Year} & \textbf{Milestone} \\ \midrule 1965 & Yamasa Tokei Keiki sells the \textit{manpo-kei} \\ 2004 & Tudor-Locke \& Bassett formalize step-count categories \cite{tudorlocke2004} \\ 2008 & Tudor-Locke \& Hatano revisit the evidence \cite{tudorlocke2008} \\ 2019 & Lee et al.: mortality benefit levels off near 7{,}500 steps \cite{lee2019} \\ 2022 & del Pozo Cruz et al.: UK Biobank benefits continue to 10{,}000 \cite{delpozocruz2022} \\ 2023 & BJSM editorial names the myth outright \cite{stamatakis2023} \\ 2025 & Ding et al.: 7{,}000 steps captures most measurable benefit \cite{ding2025} \\ \bottomrule \end{tabular} \end{center} %============================================================================ \section{Fifty Years Later, Someone Finally Checks} The first serious attempt to measure where the real curve bends, rather than argue about where marketing put it, followed 16{,}741 women with a mean age of 72 for a mean of 4.3 years, during which 504 died \cite{lee2019}. Sorted into quartiles by median daily steps --- 2{,}718, 4{,}363, 5{,}905, and 8{,}442 --- their adjusted mortality hazard ratios came out at 1.00 (reference), 0.59, 0.54, and 0.42. The paper's own description of the shape is direct: mortality risk ``progressively decreased before leveling at approximately 7{,}500 steps/day'' \cite{lee2019}. Not 10{,}000, and not a hard wall either: a curve that keeps softening as it climbs and eventually goes nearly flat. A second large cohort complicated the picture rather than closing it. A 2022 analysis of 78{,}500 UK Biobank participants, followed for a median of seven years, reported that benefits for mortality, cancer, and cardiovascular disease kept accruing up to 10{,}000 steps a day, and that stepping cadence carried an independent protective association \cite{delpozocruz2022}. Two well-conducted cohorts, two different apparent ceilings --- exactly the disagreement a single study cannot resolve, and exactly what a pooled, multi-cohort, multi-outcome review exists to adjudicate. %============================================================================ \section{What the 2025 Meta-Analysis Actually Did} Ding and colleagues searched PubMed and CINAHL for prospective studies published between January 2014 and February 2025 that measured daily steps with a wearable device, rather than by self-report, in adult populations \cite{ding2025}. That device requirement matters: self-reported step counts are notoriously unreliable, and restricting the review to accelerometer- and pedometer-measured data is a large part of why this synthesis is more trustworthy than the folklore it replaces. The search returned 57 studies across 35 cohorts for the systematic review, covering eight outcome domains (mortality, cardiovascular disease, cancer, type~2 diabetes, dementia, depressive symptoms, falls, and physical function); 31 studies across 24 cohorts were pooled into formal dose-response meta-analyses. Every comparison below is against a reference of 2{,}000 steps a day, chosen as a realistic low-activity baseline rather than zero. %============================================================================ \section{Seven Thousand, Compared to Two Thousand} Table~\ref{tab:hazards} collects every headline hazard ratio the review reports for 7{,}000 vs.\ 2{,}000 steps a day, along with the shape each outcome was classified under. \begin{table}[htbp] \centering \small \begin{tabular}{lccl} \toprule \textbf{Outcome} & \textbf{HR} & \textbf{95\% CI} & \textbf{Dose-response shape} \\ \midrule All-cause mortality & 0.53 & 0.46--0.60 & non-linear, inflection $\sim$5{,}000--7{,}000 \\ Dementia & 0.62 & 0.53--0.73 & non-linear, inflection $\sim$5{,}000--7{,}000 \\ Falls & 0.72 & -- & non-linear, inflection $\sim$5{,}000--7{,}000 \\ CVD incidence & 0.75 & 0.67--0.85 & non-linear, inflection $\sim$5{,}000--7{,}000 \\ \midrule CVD mortality & 0.53 & -- & linear, no reported plateau \\ Cancer mortality & 0.63 & -- & linear, no reported plateau \\ Depressive symptoms & 0.78 & 0.73--0.83 & linear, no reported plateau \\ Type~2 diabetes & 0.86 & -- & linear, no reported plateau \\ Cancer incidence & 0.94 & 0.87--1.01 & linear; \textit{not significant} \\ \bottomrule \end{tabular} \caption{Hazard ratios for 7{,}000 vs.\ 2{,}000 steps/day, and the dose-response shape the review assigns to each outcome. Cells marked ``--'' are reported by the review only as a point percentage, without a pooled confidence interval as precise as the other rows. Source: \cite{ding2025}.} \label{tab:hazards} \end{table} The review also rates its own certainty in this evidence: moderate for most outcomes, but explicitly low for cardiovascular mortality, cancer incidence, and physical function, and \emph{very} low for falls \cite{ding2025} --- four of the nine rows above. The cancer incidence row is the clearest illustration sitting in the data itself: a hazard ratio of 0.94 with a confidence interval running from 0.87 to 1.01 is, by the conventional threshold, not distinguishable from no effect at all. %============================================================================ \section{Does the Curve Actually Plateau?} This is the part popular coverage of the study tends to flatten out, and the part we found genuinely interesting: the review does not report one dose-response shape. It reports two. For all-cause mortality, cardiovascular disease incidence, dementia, and falls, the paper describes ``an inverse non-linear dose-response association, with inflection points at around 5{,}000--7{,}000 steps per day'' \cite{ding2025}. That is a real plateau in the statistical sense: the curve keeps falling as steps increase, but its slope softens sharply past that range, so each additional thousand steps buys noticeably less than the thousand before it did. It is a diminishing-returns curve, not a cliff --- nothing in the data suggests that walking 9{,}000 steps instead of 7{,}000 causes harm, or that the curve goes flat as a rule rather than merely soft. For cardiovascular disease mortality, cancer incidence, cancer mortality, type~2 diabetes incidence, and depressive symptoms, the paper reports something different: ``an inverse linear association'' \cite{ding2025}. No inflection point is described for these outcomes within the range the included studies covered. The practical reading is blunt: for this half of the outcome list, the data simply do not show a step count at which more stops helping. Seven thousand is a reasonable target if mortality and dementia are what concern you most. It is not obviously a ceiling if cardiovascular or cancer mortality specifically is the outcome in question. %============================================================================ \section{The Club's Arithmetic: Seventy Percent of a Slogan} None of the arithmetic in this section is the paper's. It is ours, done on top of the paper's headline number and a widely used, independently sourced walking-distance approximation, and we label it that way throughout. The fraction is the easy part: \begin{equation} \frac{7{,}000}{10{,}000} = 0.70 = 70\%. \end{equation} The sixty-year-old slogan was asking for roughly three-tenths more daily walking than the best current pooled evidence says is doing most of the measurable work for mortality, cardiovascular incidence, dementia, and falls. Turning that into distance takes one more assumption, which we borrow rather than derive: a commonly cited average-adult-stride approximation puts 10{,}000 steps at roughly 8~km, or about 5~miles. Scaling that figure by our 0.70 fraction --- simple proportion, nothing the \textit{Lancet Public Health} paper itself calculates --- gives \begin{equation} 7{,}000 \text{ steps} \approx 0.70 \times 8\text{ km} = 5.6\text{ km} \approx 3.5\text{ miles}. \end{equation} The gap between the two targets, 3{,}000 steps, is \begin{equation} 8\text{ km} - 5.6\text{ km} = 2.4\text{ km} \approx 1.5\text{ miles} \end{equation} of daily walking the marketing number was demanding on top of what the pooled evidence associates with most of the benefit. \begin{center} \small \begin{tabular}{lrr} \toprule \textbf{Target} & \textbf{Steps} & \textbf{Distance (club estimate)} \\ \midrule The slogan (1965) & 10{,}000 & $\approx$ 8.0~km ($\approx$ 5.0~mi) \\ The evidence (2025) & 7{,}000 & $\approx$ 5.6~km ($\approx$ 3.5~mi) \\ \midrule Gap & 3{,}000 & $\approx$ 2.4~km ($\approx$ 1.5~mi) \\ \bottomrule \end{tabular} \end{center} %============================================================================ \section{Why the Wrong Number Won for Sixty Years} It is worth pausing on why a number with no clinical origin outcompeted decades of more careful, more hedged research communication. Part of the answer is design: 10{,}000 is round, easy to remember, and works identically as a marketing spec or a software default regardless of what any given dose-response curve says, which made it frictionless for pedometer companies, and later phone and wearable manufacturers, to keep reusing without ever justifying it clinically. Part of the answer is institutional: the World Health Organization's actual physical-activity guidance is framed in minutes of moderate-to-vigorous activity per week, not steps at all \cite{who2020guidelines} --- there was never an official step-count guideline for journalists or app developers to cite instead, so the pre-existing folk number filled the vacuum by default. And part of the answer is that overturning folklore this entrenched needed more than one good study. The 2019 cohort of older women was compelling, but it was one demographic, one country's health system, one relatively short follow-up window \cite{lee2019}. It took a review spanning 57 studies and eight outcome domains before public health communicators had something with the breadth to plausibly replace a sixty-year-old slogan rather than merely footnote it. %============================================================================ \section{What the Paper Does Not Settle} The authors do not claim to have retired 10{,}000 as a target. Their own stated conclusion is that ``10{,}000 steps per day can still be a viable target for those who are more active,'' alongside the finding that 7{,}000 is ``associated with clinically meaningful improvements in health outcomes and might be a more realistic and achievable target for some'' \cite{ding2025}. That is a considerably more modest claim than ``science debunks 10{,}000 steps,'' and it is the one we think the evidence actually supports. Several open questions remain outside this review's reach. It cannot separate the contribution of walking speed or cadence from raw step count, a variable the 2022 UK Biobank study found to matter independently \cite{delpozocruz2022}. It pools studies across different devices, populations, and follow-up lengths, a strength for generalizability and a weakness for precision. And because every included study is observational, none of this establishes that walking more \emph{causes} the outcomes it is associated with, only that the two reliably travel together across dozens of independent cohorts. %============================================================================ \section{The Actual Takeaway} If you are walking closer to 2{,}000 steps a day than 7{,}000, the marginal value of your next thousand steps is large under this dataset, regardless of which round number you are technically chasing. If you are already well past 7{,}000, the mortality, cardiovascular-incidence, dementia, and fall-risk curves suggest you have likely captured most of what device-measured step count alone predicts for those four outcomes, and chasing 10{,}000 specifically buys comparatively little more on them. If cardiovascular or cancer mortality is what worries you most, this dataset does not hand you a number at which to stop; those associations kept strengthening in a straight line across the whole range the included studies measured. The number that started this whole field of study was never a finding. It was a product name that got lucky enough to sound plausible for sixty years. The number that should probably replace it in your head is not really 7{,}000 either --- it is the shape of nine different curves, four of which bend and five of which don't, none of which particularly cares what a 1965 clock company decided sounded good on a dial. %============================================================================ \begin{thebibliography}{9} \bibitem{ding2025} Ding, D., Nguyen, B., Nau, T., Luo, M., del Pozo Cruz, B., Dempsey, P.~C., Munn, Z., Jefferis, B.~J., Sherrington, C., Calleja, E.~A., Chong, K.~H., Davis, R., Francois, M.~E., Tiedemann, A., Biddle, S.~J.~H., Okely, A., Bauman, A., Ekelund, U., Clare, P. \& Owen, K. (2025). Daily steps and health outcomes in adults: a systematic review and dose-response meta-analysis. \textit{The Lancet Public Health} 10(8), e668--e681. doi:10.1016/S2468-2667(25)00164-1 \bibitem{lee2019} Lee, I.-M., Shiroma, E.~J., Kamada, M., Bassett, D.~R., Matthews, C.~E. \& Buring, J.~E. (2019). Association of step volume and intensity with all-cause mortality in older women. \textit{JAMA Internal Medicine} 179(8), 1105--1112. doi:10.1001/jamainternmed.2019.0899 \bibitem{tudorlocke2004} Tudor-Locke, C. \& Bassett, D.~R. (2004). How many steps/day are enough? Preliminary pedometer indices for public health. \textit{Sports Medicine} 34(1), 1--8. doi:10.2165/00007256-200434010-00001 \bibitem{tudorlocke2008} Tudor-Locke, C., Hatano, Y., Pangrazi, R.~P. \& Kang, M. (2008). Revisiting ``how many steps are enough?'' \textit{Medicine \& Science in Sports \& Exercise} 40(7 Suppl 1), S537--S543. doi:10.1249/MSS.0b013e31817c7133 \bibitem{stamatakis2023} Stamatakis, E., Ahmadi, M.~N., Murphy, M.~H., Chico, T.~J.~A., Milton, K., del Pozo Cruz, B., Katzmarzyk, P.~T., Lee, I.-M. \& Gill, J.~M.~R. (2023). Journey of a thousand miles: from `Manpo-Kei' to the first steps-based physical activity recommendations. \textit{British Journal of Sports Medicine} 57(19), 1227--1228. doi:10.1136/bjsports-2023-106869 \bibitem{delpozocruz2022} del Pozo Cruz, B., Ahmadi, M.~N., Lee, I.-M. \& Stamatakis, E. (2022). Prospective associations of daily step counts and intensity with cancer and cardiovascular disease incidence and mortality and all-cause mortality. \textit{JAMA Internal Medicine} 182(11), 1139--1148. doi:10.1001/jamainternmed.2022.4000 \bibitem{who2020guidelines} Bull, F.~C., Al-Ansari, S.~S., Biddle, S., Borodulin, K., Buman, M.~P., Cardon, G., et al. (2020). World Health Organization 2020 guidelines on physical activity and sedentary behaviour. \textit{British Journal of Sports Medicine} 54(24), 1451--1462. doi:10.1136/bjsports-2020-102955 \end{thebibliography} \end{document}